New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareMGF (Mechano Growth Factor) vs Eloralintide

MGF (Mechano Growth Factor) vs Eloralintide

Side-by-side comparison of key properties, dosing, and research.

Anabolic & IGF
MGF (Mechano Growth Factor)
GLP-1 / Weight Loss Agonists
Eloralintide
Summary
MGF (Mechano Growth Factor) is a splice variant of IGF-1 that is locally produced in muscle tissue in response to mechanical damage from exercise. It activates muscle satellite cells (stem cells) to proliferate and repair damaged fibers, making it specifically targeted at exercise-induced hypertrophy.
Eloralintide is a long-acting amylin analog under development by OPKO Health. Amylin is co-secreted with insulin and regulates post-meal glucose by slowing gastric emptying, suppressing glucagon, and promoting satiety. Eloralintide is designed for once-weekly dosing, differentiating it from the short-acting pramlintide (Symlin). It is being studied for obesity and type 2 diabetes as a complement to GLP-1 based therapies.
Half-Life
Native MGF: minutes. PEG-MGF: ~3 days
~7 days (estimated, long-acting design)
Admin Route
SubQ, IM
SubQ
Research
Typical Dose
200–400 mcg
Under investigation in Phase 1/2 trials
Frequency
1–2 times per week
Once weekly
Key Benefits
  • Activates muscle satellite cells for repair and growth
  • Accelerates recovery from muscle damage
  • Synergistic with IGF-1 LR3 (different mechanisms)
  • Promotes muscle hypertrophy specifically at exercised muscles
  • Faster recovery between training sessions
  • Potential for injury repair in connective tissue
  • Once-weekly dosing (vs multiple daily injections for pramlintide)
  • Appetite suppression via central amylin receptor activation
  • Reduction in post-meal glucagon secretion
  • Complementary mechanism to GLP-1 agonists for combination therapy
  • Slows gastric emptying for prolonged satiety
  • Potential additive weight loss when combined with GLP-1 agents
Side Effects
  • Muscle soreness (satellite cell activation)
  • Injection site irritation
  • Hypoglycemia risk (modest, less than IGF-1 LR3)
  • Nausea
  • Vomiting
  • Decreased appetite
  • Injection site reactions
  • +1 more
Stacks With